Eli Lilly and Company (NYSE:LLY) has released its Q1 2026 earnings call presentation, reporting strong financial results. The company's EPS of $8.55 b...
Neutral
Pacific Park Financial Inc. acquired a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according to the company in its...
Neutral
AMG National Trust Bank lifted its holdings in Eli Lilly and Company (NYSE:LLY – Free Report) by 7.0% during the fourth quarter, according to its most...
Bullish
Arlington Trust Co LLC significantly reduced its stake in Eli Lilly and Company (LLY) by selling 2,113 shares, decreasing its position by 92.8% in the...
Bullish
Following Eli Lilly and Company's (LLY) acquisition of Kelonia Therapeutics, analysts have reiterated a bullish outlook on the stock. Barclays maintai...
Neutral
Eli Lilly and Company's new oral weight loss drug, Foundayo, was prescribed 3,707 times in its second week on the market in the U.S., following 1,390 ...
Bullish
Eli Lilly and Company is considered a top stock to buy despite market downturns, largely due to its strategic acquisition of Kelonia Therapeutics for ...
Neutral
Cottage Street Advisors LLC decreased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 32.8% during the fourth quarter, according to its...
Bullish
Google's 2026 Discover Core Update is fundamentally changing how investors receive information about stocks like Eli Lilly and Company, shifting from ...
Neutral
Eli Lilly is a leader in the obesity treatment market with its GLP-1 drugs Mounjaro and Zepbound, driving significant revenue growth. The company's st...
Neutral
BOCHK Asset Management Ltd increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 216.5% in the 4th quarter, according to its most r...